Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy

Journal of Investigational Allergology and Clinical Immunology

Volumn 16, Issue 2, 2006, Pages 79-85

  Roll, A ^a   Hofbauer, G ^a   Ballmer Weber, B K ^a   Schmid Grendelmeier, P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Honeybee; Hymenoptera venom allergy; Safety; Side effects; Ultra rush immunotheraphy; Wasp

Indexed keywords

ALK SQ; ANTIHISTAMINIC AGENT; BEE VENOM; CETIRIZINE; CORTICOSTEROID DERIVATIVE; FEXOFENADINE; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; TRYPTASE; WASP VENOM;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOTHERAPY; INSECT ALLERGY; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SKIN TEST; SWELLING;

ADOLESCENT; ADULT; AGED; ANIMALS; BEE VENOMS; BEES; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WASP VENOMS; WASPS;

EID: 33744484498     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Muller U, Heibling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89(2):529-35.
2. Singh RD, Bhagat A, Pandey AK. Bilateral ptosis following wasp sting. J Assoc Physicians India 2003;51:828-9.
3. Raucq E, Dupuis MJ. Facial diplegia after hymenoptera sting. Acta Neurol Belg 1998;98(2):215-20.
4. Rueff F, Przybilla B. Ultrarush immunotherapy in patients with Hymenoptera venom allergy. J Allergy Clin Immunol 2001;107(5):928-9.
5. Brehler R, Wolf H, Kutting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000;105(6 Pt 1):1231-5.
6. Przbilla B, Ring J, Griesshammer B, Braun-Falco O. [Rush hyposensitization with Hymenoptera venoms. Tolerance and results of therapy]. Dtsch Med Wochenschr 1987;112(11):416-24.
7. Wenzel J, Meissner-Kraemer M, Bauer R, Bieber T, Gerdsen R. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy 2003;58(11):1176-9.
8. Sturm G, Kranke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patient. J Allergy Clin Immunol 2002;110(6):928-33.
9. Cadario G, Marengo F, Ranghino E, Rossi R, Gatti B, Cantone R, Bona F, Pellegrino R, Feyles G, Puccinelli P, Burastero SE. Higher frequency of early local side effects with aqueous versus depot immunotherapy for hymenoptera venom allergy. J Investig Allergol Clin Immunol 2004;14(2):127-33.
10. Mellerup MT, Hagn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects durings induction treatmen. Clin Exp Allegy 2000;30(10):1423-9.
11. Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994;73(5):423-8.
12. Bosuquet J, Muller UR, Dreborg S, Jarisch R, Malling HJ, Mosbech H, Urbanek R, Youlten L. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy 1987;42(6):401-13.
13. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966;3(4):331-3.
14. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993;23(3):226-30.
15. Schivino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, Lombardo C, Roncallo C, Patriarca G. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 2004;92(4):409-13.
16. Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors: Clin Exp Allergy 2003;33(1):58-64.
17. Jarisch R, Gotz M, Aberer W, Sidi R, Stabel A, Zajc J, Fordos A. Reduction of side effects of specific immunotherapy by premedication with antihistaminics and reduction of maximal dosage to 50.000 SQ-U/ml. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1988(82):163-75.
18. Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000;55(5):484-8.
19. Mosbech H, Muller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 2000;55(11):1005-10.
20. Rzany B, Przybilla B, Jarisch R, Aberer W, Dietschi R, Wuthich B, Buhler B, Frosch P, Rakoski J, Kiehn. Clinical characteristics of patients with repeated systemic reactions during speecific immunotherapy with hymenoptera venoms. A retrospective study. Allergy 1991;46(4):251-4.
21. Wyss M, Scheitlin T, Stadler BM, Wuthrich B. Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): Immunologic and clinical results of a prospective study over 3 years. Allergy 1993;48(2):81-6.
22. Youlten LJ, Atkinson BA, Lee TH. The incidence and nature of adverse reactions to injection immunotherapy in bee and wasp venom allergy. Clin Exp Allergy 1995;25(2):159-65.
23. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990;86(5):775-80.